Galectin Therapeutics Inc. (GALT)

[sunspotter]

Here’s a post from the great erniewerner to give you an idea of the shenanigans Jim Czirr and his cohorts engaged in:

Follow along with me and at the end you will understand why this company gives me indigestion. Here is the company's corporate presentation which was an SEC filing in Sep of last year.

http://www.sec.gov/Archives/edgar/data/1133416/000119312511259396/d237073dex991.htm

First, scroll down to p. 35 and make note of the 4 drug candidates for fibrosis. We have GM-CT-01 (Davanat), GM-CT-02, GR-MD-01, and GR-MD-02. GR-MD-02 is the drug candidate they plan to take into clinical trials next year for fatty liver disease.

Now scroll up to p. 15 on the same corporate presentation filed with the SEC. Look at the picture on the lower right, "Regression of Fibrosis after 4 weeks of treatment with GR-MD-01."

This picture is apparently the result of preclinical work done with GR-MD-01, a predecessor to the drug GR-MD-02. As mentioned, GR-MD-02 is the drug being taken into trials next year.

That same picture of GR-MD-01 results was part of a June 2011 Equity Research Report (p. 15) commissioned by GALT.

http://www.scribd.com/doc/42644034/Galectin-Therapeutics-Equity-Research-Report

Then on Dec 19, 2011 the company issued an update. Please take note of the picture on the left column labeled "Regression of Fibrosis after 4 weeks of treatment with GR-MD-02."

http://www.businesswire.com/news/home/20111219005344/en/Galectin-Therapeutics-Corporate-Update

Then on the company slide presentation filed with the SEC in April 2012 check p.22.

http://www.faqs.org/sec-filings/120411/PRO-PHARMACEUTICALS-INC_8-K/d332424dex991.htm

"Treatment with GR-MD-02 for four weeks shows dramatic regression of fibrosis."

If it is not obvious to you this is what I see. Multiple times in 2011 the company publishes a picture that is evidence of the efficacy of their drug GR-MD-01. Then, starting in Dec 2011, they continue using the same picture, but now attribute it to the effect of their drug GR-MD-02. Honest mistake? Typo? If you are really generous, you may choose to give them the benfit of the doubt. As a potential investor, I see it as a continueing pattern.